My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Genocea Biosciences (GNCA)
NASDAQ:GNCA
GNCA nasdaq
United States
Genocea Biosciences

Genocea Biosciences Stock Analysis & Ratings

Genocea Biosciences Stock Analysis Overview

Smart Score
6
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Genocea Biosciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

GNCA

GNCA Stock Stats

Previous Close$1.38
Open$1.42
Bid1.35 x 100
Ask1.37 x 900
Today’s Range$1.33 - $1.42
52-Week Range$1.29 - $4.04
Volume42.51K
Average Volume169.58K
Market Cap$78.13M
Beta1.42
P/E Ratio-2.6
EPS-0.53
Earnings DateFeb 17, 2022

Company Description

Genocea Biosciences

Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
Sector
Healthcare
Industry
Biotechnology
CEO
William D. Clark
Employees
72
ISIN
US3724274010
Address
100 Acorn Park Drive, Cambridge, MA, 02140, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

GNCA FAQ

What was Genocea Biosciences’s price range in the past 12 months?
Genocea Biosciences lowest stock price was $1.29 and its highest was $4.04 in the past 12 months.
    What is Genocea Biosciences’s market cap?
    Genocea Biosciences’s market cap is $78.13M.
      What is Genocea Biosciences’s price target?
      The average price target for Genocea Biosciences is $6.70. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $9.00 ,the lowest forecast is $4.50. The average price target represents 392.65% Increase from the current price of $1.36.
        What do analysts say about Genocea Biosciences?
        Genocea Biosciences’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
          When is Genocea Biosciences’s upcoming earnings report date?
          Genocea Biosciences’s upcoming earnings report date is Feb 17, 2022 which is in 80 days.
            How were Genocea Biosciences’s earnings last quarter?
            Genocea Biosciences released its earnings results on Oct 28, 2021. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.212 by $0.162.
              Is Genocea Biosciences overvalued?
              According to Wall Street analysts Genocea Biosciences’s price is currently Undervalued.
                Does Genocea Biosciences pay dividends?
                Genocea Biosciences does not currently pay dividends.
                What is Genocea Biosciences’s EPS estimate?
                Genocea Biosciences’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Genocea Biosciences have?
                Genocea Biosciences has 57,450,000 shares outstanding.
                  What happened to Genocea Biosciences’s price movement after its last earnings report?
                  Genocea Biosciences reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.212. Following the earnings report the stock price went up 14.371%.
                    Which hedge fund is a major shareholder of Genocea Biosciences?
                    Currently, no hedge funds are holding shares in GNCA

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis